Results 71 to 80 of about 876 (115)

Discovery of novel favipiravir derivatives with improved pharmacokinetic properties as anti-SFTSV agents

European Journal of Medicinal Chemistry Reports
Favipiravir is a nucleobase analogue that exhibits antiviral activities against a variety of RNA viruses. Due to the lack of antivirals to combat SFTS, an emerging tickborne epidemic caused by a RNA virus belonging to the Phenuividae family within ...
Xiaomeng He, Fan Wu, Wei Li, Runze Zhang, Ruiyang Sun, Zhihong Hu, Wu Zhong, Manli Wang   +7 more
doaj   +1 more source

Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev)

Journal of Virus Eradication
Background: While certain studies have demonstrated that antiviral treatment administered to index patients with influenza can mitigate the transmission within households, the efficacy of anti-SARS-CoV-2 agents in curtailing household transmission ...
Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Onwalee Dhissayakamol, Wilaiporn Preeyachit, Kamonwan Soonklang, Nithi Mahanonda   +10 more
doaj   +1 more source

A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021

Медицина в Кузбассе, 2023
COVID-19 has led to a major worldwide health and economic crisis, with more than 27 million people having contracted the disease and more than 800 000 deaths.
Srinivasa Jayachandra, Sadhana Sonti, Vijaya Vathsa, C.M.A. Beliappa, Praneetha Achanta   +4 more
doaj  

ICU admission and favipiravir

Northern Clinics of Istanbul, 2021
Mungmunpuntipantip, Rujittika, Wiwanitkit, Viroj   +1 more
openaire   +2 more sources

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

BMC Infectious Diseases
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2.
Viravarn Luvira, William H. K. Schilling, Podjanee Jittamala, James A. Watson, Simon Boyd, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J. Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J. Callery, Shivani Singh, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S. Aguiar, Franciele M. Santos, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mallika Imwong, Walter R. J. Taylor, Vasin Chotivanich, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas P. J. Day, Mauro M. Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J. White, the PLATCOV Collaborative Group   +35 more
doaj   +1 more source

The effect of favipiravir on fracture healing

Acta Orthopaedica et Traumatologica Turcica
Objective: The aim of this study was to evaluate the effects of favipiravir on fracture healing. Methods: Forty-eight female rats which had a femur fracture with intramedullary Kirschner wire fixation performed were divided into 6 groups; 2 control groups (C1, C2) and 4 experimental groups (F1, F2, F3, F4).
Sabir, Mehmet Ali, Celik, Ahmet Onur, Demirtas, Elif Mercan, Copuroglu, Cem   +3 more
openaire   +4 more sources

Cost-Effectiveness Analysis of Favipiravir and Remdesivir as COVID-19 Treatment in South Tangerang, Banten Province - Indonesia

Pharmacology and Clinical Pharmacy Research
COVID-19 is a contagious ailment primarily attributed to the severe acute respiratory syndrome coronavirus. Indonesia persists in confronting the COVID-19 pandemic, and South Tangerang City has emerged as one of the municipalities in Indonesia that has ...
Wahyu G. Putro, Andriani R. Fahriyati, Gilberto A. Julian, Tania R. Amalia, Zaki M. Riski   +4 more
doaj   +1 more source

Favipiravir [PDF]

Reactions Weekly, 2019
openaire   +1 more source

Favipiravir and Coronavirus

Acta Scientific Pharmaceutical Sciences, 2020
openaire   +2 more sources

REVIEW ON FAVIPIRAVIR

International Journal of Biology, Pharmacy and Allied Sciences, 2021
openaire   +1 more source